Teva Sues FDA Over New Stance On Generic-Drug Exclusivity
A new U.S. Food and Drug Administration policy threatens to deprive generic-drug makers of lucrative exclusivity even when they expose themselves to litigation by challenging patents for brand-name drugs, Teva Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article